Ultralife Non-GAAP EPS of $0.01 misses by $0.14, revenue of $43.9M beats by $3.9M
Earnings Performance: Ultralife reported a Q4 Non-GAAP EPS of $0.01, missing expectations by $0.14, while revenue was $43.9 million, beating estimates by $3.9 million but showing a 1.3% decline year-over-year.
Financial Outlook: The company had an adjusted EBITDA of $3.9 million for Q4 2024, down from $4.8 million in the previous year, with a backlog and high confidence orders totaling $102.2 million at the end of 2024, up from $78.0 million at the end of Q3.
Trade with 70% Backtested Accuracy
Analyst Views on ULBI
About ULBI
About the author
Ultralife Reports Q4 Revenue Growth Amid Losses
- Revenue Growth: Ultralife reported Q4 revenue of $48.5 million, a 10.6% year-over-year increase, with full-year revenue reaching $191.2 million, reflecting a 16.2% growth, indicating strong performance in the battery and energy products segment.
- Loss Situation: Despite revenue growth, Ultralife reported an operating loss of $10.6 million for Q4 and a full-year loss of $5.9 million, resulting in a loss of $0.35 per share, highlighting the negative impact of non-cash impairments on financials.
- Backlog Growth: The company’s backlog reached $110.2 million at the end of Q4, a 22.1% increase from the previous quarter, indicating strong future demand, particularly in the medical and industrial sectors.
- Communication System Challenges: The communication systems segment experienced a 35.2% revenue decline, primarily due to delayed orders from the US government shutdown, revealing profitability pressures faced by this segment in the short term.
Ultralife Reports Q4 Results with Revenue Growth and Improved EBITDA
- Financial Performance: Ultralife's Q4 report reveals a GAAP EPS of -$0.45, indicating a loss; however, revenue reached $48.48 million, reflecting a 10.6% year-over-year increase, showcasing the company's sales growth potential in the market.
- Adjusted EBITDA Improvement: The company's adjusted EBITDA rose to $5.7 million, up from $3.9 million in the same quarter last year, indicating enhanced operational efficiency and effective cost management.
- Increased Backlog: Ultralife's backlog stood at $110.2 million at the end of 2025, compared to $90.3 million at the end of Q3, demonstrating strong future revenue support and sustained market demand.
- Optimistic Market Outlook: Despite reporting a loss, Ultralife's revenue and EBITDA growth, along with the increase in backlog, suggest a solid development potential for the company in future market competition.
Ultralife Corporation Expands Leadership Team to Accelerate Growth Initiatives
Leadership Changes: Ultralife Corporation (NASDAQ: ULBI) has appointed Jeffrey Luke as Chief Marketing Officer and James Pope as Senior Vice President of Sales & Business Development, effective January 6, 2025.
Roles and Responsibilities: Luke will focus on corporate strategy and global operations, while Pope will drive market growth and revenue through strategic alliances, leveraging their extensive industry experience.
Company Overview: Ultralife Corporation provides power, communications, and electronic systems to commercial, military, and government clients worldwide, positioning itself among the best manganese stocks.
Investment Perspective: While ULBI is recognized as a potential investment, there are suggestions that certain AI stocks may offer better upside potential with lower risk.
Ultralife (ULBI) Q2 2025 Earnings Call Transcript
- Author's Perspective: The opinions shared in the article are solely those of the author and do not represent Nasdaq, Inc.
- Data Limitations: The information is based on data available up to October 2023.
Ultralife Corporation to Report Second Quarter Results on August 7, 2025
Ultralife Corporation Q2 Results Announcement: Ultralife Corporation will report its second quarter results on August 7, 2025, before the market opens, followed by an investor conference call and webcast at Noon ET.
Participation Details for Investors: Participants wishing to join the conference call by phone must pre-register to receive dial-in information and a personal identification number, with a live webcast also available on the company's website.
Ultralife outlines Q2 Electrochem integration and strategic growth initiatives
Financial Performance: Ultralife Corporation reported Q1 2025 sales of $50.7 million with a net income of $1.9 million, reflecting strong government-defense sales and the full contribution from the Electrochem acquisition, despite challenges such as tariff impacts and declining medical battery sales.
Outlook and Challenges: Management expressed confidence in future growth driven by operational improvements and new product lines, while acknowledging risks related to tariffs, delayed shipments, and macroeconomic uncertainties affecting revenue predictability.
Ultralife Reports Q4 Revenue Growth Amid Losses
- Revenue Growth: Ultralife reported Q4 revenue of $48.5 million, a 10.6% year-over-year increase, with full-year revenue reaching $191.2 million, reflecting a 16.2% growth, indicating strong performance in the battery and energy products segment.
- Loss Situation: Despite revenue growth, Ultralife reported an operating loss of $10.6 million for Q4 and a full-year loss of $5.9 million, resulting in a loss of $0.35 per share, highlighting the negative impact of non-cash impairments on financials.
- Backlog Growth: The company’s backlog reached $110.2 million at the end of Q4, a 22.1% increase from the previous quarter, indicating strong future demand, particularly in the medical and industrial sectors.
- Communication System Challenges: The communication systems segment experienced a 35.2% revenue decline, primarily due to delayed orders from the US government shutdown, revealing profitability pressures faced by this segment in the short term.
Ultralife Reports Q4 Results with Revenue Growth and Improved EBITDA
- Financial Performance: Ultralife's Q4 report reveals a GAAP EPS of -$0.45, indicating a loss; however, revenue reached $48.48 million, reflecting a 10.6% year-over-year increase, showcasing the company's sales growth potential in the market.
- Adjusted EBITDA Improvement: The company's adjusted EBITDA rose to $5.7 million, up from $3.9 million in the same quarter last year, indicating enhanced operational efficiency and effective cost management.
- Increased Backlog: Ultralife's backlog stood at $110.2 million at the end of 2025, compared to $90.3 million at the end of Q3, demonstrating strong future revenue support and sustained market demand.
- Optimistic Market Outlook: Despite reporting a loss, Ultralife's revenue and EBITDA growth, along with the increase in backlog, suggest a solid development potential for the company in future market competition.
Ultralife Corporation Expands Leadership Team to Accelerate Growth Initiatives
Leadership Changes: Ultralife Corporation (NASDAQ: ULBI) has appointed Jeffrey Luke as Chief Marketing Officer and James Pope as Senior Vice President of Sales & Business Development, effective January 6, 2025.
Roles and Responsibilities: Luke will focus on corporate strategy and global operations, while Pope will drive market growth and revenue through strategic alliances, leveraging their extensive industry experience.
Company Overview: Ultralife Corporation provides power, communications, and electronic systems to commercial, military, and government clients worldwide, positioning itself among the best manganese stocks.
Investment Perspective: While ULBI is recognized as a potential investment, there are suggestions that certain AI stocks may offer better upside potential with lower risk.
Ultralife (ULBI) Q2 2025 Earnings Call Transcript
- Author's Perspective: The opinions shared in the article are solely those of the author and do not represent Nasdaq, Inc.
- Data Limitations: The information is based on data available up to October 2023.
Ultralife Corporation to Report Second Quarter Results on August 7, 2025
Ultralife Corporation Q2 Results Announcement: Ultralife Corporation will report its second quarter results on August 7, 2025, before the market opens, followed by an investor conference call and webcast at Noon ET.
Participation Details for Investors: Participants wishing to join the conference call by phone must pre-register to receive dial-in information and a personal identification number, with a live webcast also available on the company's website.
Ultralife outlines Q2 Electrochem integration and strategic growth initiatives
Financial Performance: Ultralife Corporation reported Q1 2025 sales of $50.7 million with a net income of $1.9 million, reflecting strong government-defense sales and the full contribution from the Electrochem acquisition, despite challenges such as tariff impacts and declining medical battery sales.
Outlook and Challenges: Management expressed confidence in future growth driven by operational improvements and new product lines, while acknowledging risks related to tariffs, delayed shipments, and macroeconomic uncertainties affecting revenue predictability.
